https://www.onclive.com/onclive-tv/dr-shore-on-radium-223-patient-considerations
Dr. Shore on Radium-223 Patient Considerations

Neal D. Shore, MD

Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Myrtle Beach, discusses patient considerations following treatment with radium-223 for bone metastases from prostate cancer.

Radium-223 gets into bone lesions in a matter of minutes, Shore says. Radium-223 is not metabolized by a patient's kidneys or liver, it is simply decayed into fecal matter. A patient is at no real risk following infusion, but should avoid contact with fecal matter.
 
Printer Printing...